Treating cancer more selectively and more effectively – this could be achieved with an innovative technology developed by teams of researchers at the Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP) and the Ludwig-Maximilians-Universität München (LMU). The process transforms proteins and antibodies into stable, highly functional drug transporters, with which tumor cells can be detected and killed.
Classic chemotherapy for the treatment of cancer is based on toxic substances that are particularly effective for rapidly dividing cells. However, since healthy tissue also depends on cell division, treatment with chemotherapeutic substances is often accompanied by severe side effects. A dose sufficient to completely remove the tumor, would in many cases be too toxic to administer to a diseased person. With more modern approaches, it is now possible to transport active agents (drugs) in the body selectively to the site of action, for example by linking a drug with an antibody that can differentiate cancer cells from healthy tissue through changes on the surface of the cell. Five such Antibody Drug Conjugates (ADCs) are already on the market.
However, these ADCs lose a large part of their “toxic cargo” en route to the cancer cell. The substances (drugs) are released into the bloodstream and dangerous side effects can occur. A stable link between drug and antibody would therefore be highly desirable. This is precisely what the researchers – a team led by Professor Christian Hackenberger from the FMP and Professor Heinrich Leonhardt from the LMU Biocenter – focused on. Their results have been published in the prestigious journal, Angewandte Chemie: In two consecutive articles, the development of methods and the application of these methods to selective drug transport are presented.
The new drug transporters enable lower doses and less severe side effects
“We have developed an innovative technology that makes it possible to link native proteins and antibodies to complex molecules, such as fluorescent dyes or drugs more easily and with better stability than ever before,” reports Marc-André Kasper, a researcher in Christian Hackenberger’s group. The researchers discovered the outstanding properties of unsaturated phosphorus (V) compounds and took advantage of those. These phosphonamidates connect a desired modification – for example, a cancer-fighting agent – exclusively to the amino acid cysteine, in a protein or antibody. Since cysteine is a very rare natural occurring amino acid, the number of modifications per protein can be controlled quite effectively, which is essential for the construction of drug conjugates. In addition, phosphonamidates can easily be incorporated into complex chemical compounds. “The greatest achievement of the new method, however, is that the resulting bond is also stable during blood circulation,” says Marc-André Kasper. The ADCs that are on the market cannot achieve this.
To test the applicability on targeted drug delivery, the researchers compared their technology directly with the FDA-approved ADC, Adcetris®. The medication was re-created as precisely as possible with the same antibody and active agent, the only difference was that the innovative phosphonamidate linkage was used. When applied to blood serum, the researchers observed that their modified ADC lost significantly less active ingredient over a period of days. They also used the new technology in experiments with mice to combat Hodgkin’s lymphoma. The preparation proved to be more effective than the conventional medication. “From our results, we conclude that phosphonamidate-linked drug transporters can be administered in lower doses, and that side effects can be further reduced. Thus the technology has great potential to replace current methods in order to develop more effective and safer ADCs in the future,” says FMP group leader Christian Hackenberger.
In the next step, the research groups will continue their efforts in the development of ADCs based on phosphonamidates. Preclinical studies, which are essential for the treatment of patients, are already underway. In this regard, the promising start-up company Tubulis, which was awarded the Leibniz Start-Up Prize last year, functions as a platform for the further development to market maturity.
The Latest on: Antibody Drug Conjugates
via Google News
The Latest on: Antibody Drug Conjugates
- BOC Sciences Promotes Antibody Drug Conjugates Services for Drug Development Researchon August 15, 2019 at 8:33 am
BOC Sciences announces to promote its antibody drug conjugate service for scientists engaged with drug R&D both academically and industrially. New York - August 15, 2019 - Having been one of the world ...
- Global Antibody Drug Conjugates Market Size, Statistics, Industry Growth, Value Chain, Trends And Forecast To 2025on August 8, 2019 at 12:39 am
Aug 08, 2019 (Garth Media via COMTEX) -- This report studies theglobal Antibody Drug Conjugates marketstatus and forecast, categorizes the global Antibody Drug Conjugates market size (value amp; ...
- Dr. Mei on Investigational CAR T-Cell Therapies and Antibody-Drug Conjugates in Hodgkin Lymphomaon August 5, 2019 at 1:06 pm
Matthew G. Mei, MD, assistant clinical professor, Department of Hematology and Hematopoietic Cell Transplantation, and hematologist/oncologist, City of Hope, discusses investigational CAR T-cell ...
- Global Antibody Drug Conjugates Market Expected to Reach $3,198 Million by 2023on August 2, 2019 at 9:15 pm
Before it's here, it's on the Bloomberg Terminal.
- Antibody Drug Conjugate Market Size Is Estimated To Grow at a CAGR of 19% Till 2023 | Industry Trends, Key Players and Global Market Analysis By MRFRon July 31, 2019 at 12:06 am
Pune, India, July 31, 2019 (GLOBE NEWSWIRE) -- The Global Antibody Drug Conjugate Market is about to experience an astounding CAGR of 19% during the forecast period (2017-2023) by Market Research ...
- Global Cancer Antibody Drug Conjugates Market Research Report 2019 by Manufacturers, Regions, Types and Applicationson July 10, 2019 at 12:19 am
In this report, our team research the global Cancer Antibody Drug Conjugates market by type, application, region and manufacturer 2013-2018 and forcast 2019-2024. For the region, type and application, ...
- Click chemistry targets antibody-drug conjugates for the clinicon July 5, 2019 at 8:56 am
Researchers at the Memorial Sloan Kettering Cancer Center in New York are preparing the first test in humans of a new type of diagnostic that combines a radioisotope and antibody via bioorthogonal ...
- Antibody Drug Conjugate Market to Reach Approximately USD 10.1 Bn by 2026on July 4, 2019 at 4:48 am
The Global Antibody Drug Conjugate Market size is expected to reach USD 10.1 Billion by 2026 and growing CAGR around 26.3% during the forecast period 2018 to 2026. The Global Antibody Drug Conjugate ...
- New Antibody-Drug Conjugate Shrinks HER2+ Cancerson July 2, 2019 at 4:41 am
A new antibody-drug conjugate that couples trastuzumab (multiple brands), a mainstay of treatment for HER2+ cancers, with duocarmycin, a cytotoxic byproduct of a strain of bacteria, has shown what ...
- AbbVie antibody-drug conjugate flunks late-stage brain cancer study; shares down 2% premarketon May 17, 2019 at 6:31 am
A Phase 3 clinical trial, INTELLANCE-1, evaluating AbbVie's (NYSE:ABBV) antibody-drug conjugate (ADC) depatuxizumab mafodotin (Depatux-M, previously named ABT-414) in patients with newly diagnosed ...
via Bing News